Cargando…

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis

BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wicks, Paul, Rasouliyan, Lawrence, Katic, Bo, Nafees, Beenish, Flood, Emuella, Sasané, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015319/
https://www.ncbi.nlm.nih.gov/pubmed/27604188
http://dx.doi.org/10.1186/s13104-016-2243-8
_version_ 1782452416782794752
author Wicks, Paul
Rasouliyan, Lawrence
Katic, Bo
Nafees, Beenish
Flood, Emuella
Sasané, Rahul
author_facet Wicks, Paul
Rasouliyan, Lawrence
Katic, Bo
Nafees, Beenish
Flood, Emuella
Sasané, Rahul
author_sort Wicks, Paul
collection PubMed
description BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were recruited from an online patient community and completed an online survey about treatment side effects, discontinuation, and satisfaction. RESULTS: 281 patients in four groups completed the survey: currently receiving fingolimod (CF, N = 61), currently receiving dimethyl fumarate (CDMF, N = 129), discontinued fingolimod (DF, N = 32) and discontinued dimethyl fumarate (DDMF, N = 59). Reasons for treatment switch were to take oral treatment (CF: 63.3 %, CDMF: 61.8 %), side effects of prior medication (CF: 67.3 %, CDMF: 44.1 %) and lack of effectiveness of prior medication (CF: 38.8 %, CDMF: 31.4 %). Main reasons for discontinuation were side effects (DF: 46.9 %, DDMF: 67.8 %) and lack of effectiveness (DF: 25.0 %, DDMF: 15.3 %). CDMF patients had an increased risk of abdominal pain, flushing, diarrhea, and nausea. Treatment satisfaction was highest among CF patients followed by CDMF, DF, and then DDMF patients. CONCLUSIONS: Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate were more likely to experience a side effect versus patients currently taking fingolimod. Examination of the relationship between tolerability and adherence/persistence is needed.
format Online
Article
Text
id pubmed-5015319
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50153192016-09-09 The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis Wicks, Paul Rasouliyan, Lawrence Katic, Bo Nafees, Beenish Flood, Emuella Sasané, Rahul BMC Res Notes Research Article BACKGROUND: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. OBJECTIVES: To compare patient-reported experiences of fingolimod and dimethyl fumarate. METHODS: Adult relapsing-remitting multiple sclerosis patients treated with fingolimod or dimethyl fumarate were recruited from an online patient community and completed an online survey about treatment side effects, discontinuation, and satisfaction. RESULTS: 281 patients in four groups completed the survey: currently receiving fingolimod (CF, N = 61), currently receiving dimethyl fumarate (CDMF, N = 129), discontinued fingolimod (DF, N = 32) and discontinued dimethyl fumarate (DDMF, N = 59). Reasons for treatment switch were to take oral treatment (CF: 63.3 %, CDMF: 61.8 %), side effects of prior medication (CF: 67.3 %, CDMF: 44.1 %) and lack of effectiveness of prior medication (CF: 38.8 %, CDMF: 31.4 %). Main reasons for discontinuation were side effects (DF: 46.9 %, DDMF: 67.8 %) and lack of effectiveness (DF: 25.0 %, DDMF: 15.3 %). CDMF patients had an increased risk of abdominal pain, flushing, diarrhea, and nausea. Treatment satisfaction was highest among CF patients followed by CDMF, DF, and then DDMF patients. CONCLUSIONS: Discontinuation was driven by experience of side effects. Patients currently taking dimethyl fumarate were more likely to experience a side effect versus patients currently taking fingolimod. Examination of the relationship between tolerability and adherence/persistence is needed. BioMed Central 2016-09-07 /pmc/articles/PMC5015319/ /pubmed/27604188 http://dx.doi.org/10.1186/s13104-016-2243-8 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wicks, Paul
Rasouliyan, Lawrence
Katic, Bo
Nafees, Beenish
Flood, Emuella
Sasané, Rahul
The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
title The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
title_full The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
title_fullStr The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
title_full_unstemmed The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
title_short The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
title_sort real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015319/
https://www.ncbi.nlm.nih.gov/pubmed/27604188
http://dx.doi.org/10.1186/s13104-016-2243-8
work_keys_str_mv AT wickspaul therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT rasouliyanlawrence therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT katicbo therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT nafeesbeenish therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT floodemuella therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT sasanerahul therealworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT wickspaul realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT rasouliyanlawrence realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT katicbo realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT nafeesbeenish realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT floodemuella realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis
AT sasanerahul realworldpatientexperienceoffingolimodanddimethylfumarateformultiplesclerosis